Hemophilia News and Research

RSS

Hemophilia is a rare, inherited bleeding disorder in which your blood doesn’t clot normally. If you have hemophilia, you may bleed for a longer time than others after an injury. You also may bleed internally, especially in your knees, ankles, and elbows. This bleeding can damage your organs or tissues and, sometimes, be fatal.

LFB completes conversion of all acquired preferred stock

GTC Biotherapeutics, Inc. announced that LFB Biotechnologies, a wholly owned subsidiary of LFB S.A. (Laboratoire Français du Fractionnement et des Biotechnologies S.A., Les Ulis, France) and a strategic shareholder in GTC, has converted the convertible preferred stock it previously purchased in November 2009 under the terms described in the financing agreements approved by GTC shareholders in July 2009 into a total of 5.3 million shares of common stock.

9 Jan 2010

AMT receives Innovation Credit to develop gene therapy treatment for DMD

Amsterdam Molecular Therapeutics, a leader in the field of human gene therapy, announced today that it will receive an Innovation Credit of up to EUR 4 million from the Dutch government to support the development of AMT's gene therapy treatment for Duchenne Muscular Dystrophy (DMD).

6 Jan 2010

Rh-negative blood supply prioritized as tri-state area braces for winter months

New York Blood Center (NYBC) serving New York City, Long Island, Hudson Valley and New Jersey calls upon the community to please donate blood today. Blood drive cancellations from the weekend storm of December 19, 2009, coupled with unusually high demand from regional hospitals, have impacted Rh-negative blood supplies, especially type O-negative.

31 Dec 2009

NYBC calls for blood donation in recognition of National Blood Donor Month

New York Blood Center (NYBC) and its divisions in Manhattan, Long Island, Hudson Valley, Brooklyn/Staten Island, and New Jersey call upon the community to please donate blood, in recognition of National Blood Donor Month, and to help save lives.

30 Dec 2009

CSL Behring awards four advocacy grants to patient organizations in the U.S.

CSL Behring, a global leader in the plasma-protein biotherapies industry and a subsidiary of CSL Limited, has awarded four advocacy grants totaling $87,000 to patient organizations in the United States through the Local Empowerment for Advocacy Development (LEAD) program.

29 Dec 2009

Tel Aviv University's new Genome Analyzer fuels research dreams and tomorrow's cures

To identify the hemophilia mutation that affected Queen Victoria and her European relatives, scientific detectives used a cutting-edge "deep sequencing tool." Able to trace rare genetic disease mutations, the tool can turn a single laboratory into a fertile genetic research center.

22 Dec 2009

HFA urges American Red Cross to end current labor issues over blood supply

The Hemophilia Federation of America (HFA) expresses its concern regarding the ongoing labor issues involving the Teamsters Local 929 and the American Red Cross of Pennsylvania /New Jersey.

15 Dec 2009

McMaster University launches first online interactive educational program on bleeding disorders

McMaster University, in partnership with the Canadian Hemophilia Society and Bayer HealthCare Pharmaceuticals, has launched Canada's first online, interactive educational program on bleeding disorders. The program, Emergency Management of Bleeding Disorders, is available free to all Canadian health professionals to learn about the signs, symptoms, diagnosis and treatment of bleeding disorders.

10 Dec 2009

Specialty pharmaceutical market: Treatment patterns and product performance

IMS Health, the world’s leading provider of market intelligence to the pharmaceutical and healthcare industries, today announced the wide-scale availability of its advanced analytical offering, IMS Specialty Market Dynamics™, which delivers the most complete view of treatment patterns and product performance in the rapidly growing specialty pharmaceutical market.

8 Dec 2009

Amber Pharmacy receives ACHC accreditation

Amber Pharmacy announced today that it received accreditation by the Accreditation Commission for Health Care, Inc. (ACHC) for specialized pharmacy services.

4 Dec 2009

NHLBI awards new federal grant to improve the quality of stored transfusion blood

A new, $2.8 million, four-year federal grant will support researchers at the University of Pittsburgh School of Medicine and their collaborators at Wake Forest University as they study why the quality of stored transfusion blood degrades over time and how to address the problem.

3 Dec 2009

Wyeth pledges more than 40 million IUs of factor concentrates to WFH

As part of its continued commitment to hemophilia care around the world, Wyeth, now a part of Pfizer, has pledged more than 40 million international units (IUs) of factor concentrates to the World Federation of Hemophilia (WFH).

3 Dec 2009

NHLBI awards stimulus funds for hemophilia drug research

PTC Therapeutics, Inc. (PTC) today announced the receipt of a $1 million Challenge Grant award from the National Heart, Lung, and Blood Institute (NHLBI) as part of the National Institutes of Health (NIH).

2 Dec 2009

FDA approves additional intended use of Roche's cobas TaqScreen MPX Test

Roche announced today that the United States Food & Drug Administration (FDA) approved an additional intended use for its licensed nucleic acid test, to screen source plasma in pools comprised of up to 96 individual donations. The test, called the cobas® TaqScreen MPX Test for use on the cobas s 201 system, is a qualitative, in-vitro test for the simultaneous, direct detection of the human immunodeficiency virus (HIV-1 Group M RNA, HIV-1 Group O RNA , HIV-2 RNA), hepatitis C virus RNA and hepatitis B virus DNA in human plasma.

From Roche Sequencing and Life Science 2 Dec 2009

Canadians with hemophilia A can use new treatment option, XYNTHA

Canadians with hemophilia A - a rare, inherited blood-clotting disorder - now have a new treatment option with the introduction of XYNTHA(TM), a recombinant factor VIII product for both the control and prevention of bleeding episodes and surgical prophylaxis.

2 Dec 2009

Therapeutic agents in soy can treat colon cancer, says study

A study conducted by Children's Hospital & Research Center Oakland scientists identifies a new class of therapeutic agents found naturally in soy that can prevent and possibly treat colon cancer, the third most deadly form of cancer. Sphingadienes (SDs) are natural lipid molecules found in soy that research shows may be the key to fighting colon cancer.

24 Nov 2009

Lysteda tablets to treat menorrhagia approved by the FDA

The U.S. Food and Drug Administration today approved Lysteda tablets (tranexamic acid), the first non-hormonal product cleared to treat heavy menstrual bleeding (menorrhagia). Lysteda works by stabilizing a protein that helps blood to clot.

24 Nov 2009

Amsterdam Molecular Therapeutics provides third-quarter 2009 business updates

Amsterdam Molecular Therapeutics, a leader in the field of human gene therapy, today provides its non-audited business update in compliance with the EU transparency directive. This report summarizes material events and AMT's financial position for the third quarter of 2009.

18 Nov 2009

Lack of hemophilia treatment in the developing world costing lives

When modern medicine finds a way to treat a medical condition, people often think that the problem is solved. But we also have to find ways to get that treatment into the hands of those who need it. For example, new research from North Carolina State University shows that much more needs to be done to help get existing treatment to hemophilia patients in the developing world, and that the current lack of treatment there is costing lives.

16 Nov 2009

Baxter International lauds new Medicare education benefit for chronic kidney disease patients

Baxter International Inc. commends the Centers for Medicare and Medicaid Services (CMS) on announcing implementation plans for a new Medicare benefit that will provide Stage 4 chronic kidney disease patients with coverage for up to six sessions explaining their treatment options, such as transplantation, home peritoneal dialysis (PD), home hemodialysis (HHD) or clinic-based hemodialysis (HD).

From Baxter International Inc. 10 Nov 2009